The purpose of this study is to determine whether AGuIX (Activation and Guidance of Irradiation by X-ray) gadolinium-based nanoparticles make radiation work more effectively in the treatment of patients with brain metastases that are more difficult to control with stereotactic radiation alone.
Melanoma with intracranial growth consistent with tumor progression despite immunotherapy
Gastrointestinal primary
HER2 positive breast cancer (subtype assessed using most representative tissue available in opinion of enrolling clinician and/or study PI)
Cystic metastases
Participants who cannot undergo a brain MRI
Participants who cannot receive gadolinium
Participants with widespread, definitive leptomeningeal disease
Patients requiring radiation to either >10 targets (if naïve to whole brain radiation) or >20 targets (if whole brain radiation has been given previously) per the discretion of the treating clinician and/or study PI
Brigham and Women's Hospital
Lead sponsor
Dana-Farber Cancer Institute
Collaborator
TherAguix
Collaborator